2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers Lain Anderson TJ Bilodeau Read more
Related Practice Life Sciences & Pharma In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations. 01052021090143
Published Articles Life Sciences & Pharma Biopharma predictions for 2026: thoughts from LEK Consulting’s Simon Middleton January 14, 2026
Article Contract/Pharma Services Indonesia’s Clinical Trial Ecosystem: From Potential to Performance November 25, 2025
Special Report Contract/Pharma Services Advancing Innovation and Global Reach: The Next Chapter in China’s Clinical Trial… November 12, 2025
Special Report Life Sciences & Pharma On the Cusp of a Cure: Is Asia Pacific Ready for the Precision Era? (Australia) November 11, 2025
Executive Insights Life Sciences & Pharma Unleashing Growth: How Innovation Is Reshaping Animal Health September 12, 2025
Case Study Organization & Performance Procurement Excellence as Competitive Advantage: Lowering Costs to Elevate Products May 6, 2025